With concerns about radiation dose and reducing unnecessary imaging scans, advances in computed tomography (CT) systems have brought about technologies such as iterative reconstruction software, intraoperative capabilities and dose-tracking software. In addition, recent studies on the use of CT on select patient populations and the modality’s benefits in detecting certain cancers are showing that the risks of CT imaging can go both ways. While CT exams can add to a patient’s lifetime exposure to ionizing radiation, they can also be more beneficial in cases where magnetic resonance imaging (MRI) or ultrasound might not be able to detect early-stage cancers. Some of these trends in utilization indicate that appropriate low-dose CT imaging will be key across patient populations.


Based on its recent analysis of the molecular imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2013 North American Frost & Sullivan Award for Company of the Year. Siemens Healthcare has dedicated equal attention and resources to the development of both single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging – the two pillars of molecular imaging. The company has moved quickly to innovate and strategize in a rapidly evolving market to secure for itself an ideal market position.


ITN is proud to go pink this month in an effort to help bring attention to Breast Cancer Awareness Month. This disease all too often hits home with the imaging and radiation oncology markets.


This year at RSNA 2013, GE Healthcare will showcase its SenoBright Contrast Enhanced Spectral Mammography (CESM) technology designed to produce contrast-enhanced images of the breast using an approved X-ray contrast agent and a dual energy acquisition technique. This technology is experiencing increased adoption globally and in the United States, and GE Healthcare will present, in its booth, an informational campaign designed for American women with a history of breast cancer and their relatives, and those who want to know about the latest options in diagnostics.


Limiting the amount of radiation absorbed in the hippocampal portion of the brain during whole-brain radiotherapy (WBRT) for brain metastases preserves memory function in patients for up to six months after treatment according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.


At RSNA 2013, GE Healthcare will highlight the latest hardware and advanced applications for its Discovery IGS angiography platform. These updates are geared towards addressing the challenges of healthcare providers, support clinical decision making and helping clinicians in refining overall patient care.

Ascendian Healthcare Consulting announced a new service line to assist clients with ensuring the confidentiality, integrity and availability of patient data — the medical imaging client’s privacy, data security and patient safety consulting services.

Ascendian Healthcare Consulting Service Line

A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow trials of different sizes and durations to be compared easily. This measurement also helps to illustrate the high costs associated with delays.

Subscribe Now